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ABSTRACT
Tricyclo (tc)-DNA belongs to the class of conform-
ationally constrained DNA analogs that show
enhanced binding properties to DNA and RNA. We
prepared tc-oligonucleotides up to 17 nt in length, and
evaluated their binding efficiency and selectivity
towards complementary RNA, their biological
stability in serum, their RNase H inducing potential
and their antisense activity in a cellular assay. Relative
to RNA or 2′-O-Me-phosphorothioate (PS)-RNA, fully
modified tc-oligodeoxynucleotides, 10–17 nt in length,
show enhanced selectivity and enhanced thermal
stability by ∼1°C/modification in binding to RNA targets.
Tricyclodeoxyoligonucleotides are completely stable
in heat-deactivated fetal calf serum at 37°C. More-
over, tc-DNA–RNA duplexes are not substrates for
RNase H. To test for antisense effects in vivo, we
used HeLa cell lines stably expressing the human
β-globin gene with two different point mutations in
the second intron. These mutations lead to the
inclusion of an aberrant exon in β-globin mRNA.
Lipofectamine-mediated delivery of a 17mer tc-
oligodeoxynucleotide complementary to the 3′-cryptic
splice site results in correction of aberrant splicing
already at nanomolar concentrations with up to
100-fold enhanced efficiency relative to a 2′-O-Me-PS-
RNA oligonucleotide of the same length and
sequence. In contrast to 2′-O-Me-PS-RNA, tc-DNA
shows antisense activity even in the absence of
lipofectamine, albeit only at much higher oligonucle-
otide concentrations.
INTRODUCTION
Genome sequencing has identified many genes that encode
proteins whose functions are yet unknown. A number of these
proteins will undoubtedly be future targets in medicinal chem-
istry. Understanding their cellular roles requires inhibition of
their gene expression. Besides this there is a growing thera-
peutic interest in the inhibition of disease-related proteins on
the genetic level. Oligonucleotides are potent synthetic tools
for such applications, because knowledge of the target gene
sequence provides sufficient information for inhibitor design
(antisense oligonucleotides) (1,2). However, the relatively
weak affinity to complementary RNA and the short cellular
half-life of unmodified oligodeoxynucleotides requires the use
of analogs.
The first generation of analogs that are now widely used in
antisense applications are the phosphorothioate (PS) oligo-
deoxynucleotides, in which one non-bridging oxygen in the
phosphodiester unit is replaced by sulfur. PS-oligonucleotides
show increased resistance to enzymic degradation while main-
taining the properties of unmodified deoxyoligonucleotides to
elicit RNase H activity (3). If coding regions of a given gene
are targeted, RNase H-mediated degradation of the mRNA at
the complexation site is an important antisense mechanism
(4,5). The relatively weak binding to RNA, however, requires
high PS-oligonucleotide concentration, which is often accompanied
by undesired and toxic non-antisense effects in vivo (6).
Second generation antisense oligonucleotides include the
2′-O-alkyl-RNAs with the 2′-O-methyl- and the 2′-O-methoxyethyl
-RNA being the most prominent representatives (7).
Typically, these analogs show enhanced biostability and
enhanced RNA affinity compared with DNA. Due to the fact
that pure 2′-O-alkyl-oligonucleotides do not elicit RNase H
activity, strategies involving chimeric oligonucleotides with a
window of deoxyribonucleotide units in the center of the
sequence, allowing for RNase H activity (gapmers), were
developed (8). With respect to therapeutic applications, about 12
antisense oligonucleotides of the first and second generation
are now in clinical trials. One PS-oligodeoxynucleotide
(Vitravene™) for the treatment of cytomegalovirus-induced
retinitis was recently approved for commercialization.
There is an ongoing challenge in the discovery of alternative
DNA or RNA structures with improved chemical and biological
properties. Besides advances in the field of the charge-neutral
polyamide nucleic acid analogs (PNAs) (9–11), the concept of
conformational pre-organization has recently proven to be very
successful and has led to a number of oligonucleotide analogs
with improved RNA-binding properties and enhanced biostability
(12–14). Particularly noteworthy are the DNA-analog hexitol-NA
(HNA) (15,16) and the RNA analog locked nucleic acid (LNA)
(17,18). Both analogs show enhanced RNA binding relative to
the 2′-O-alkyl RNAs and interesting antisense properties. A
recent contribution from our laboratory is the analog tricyclo
(tc)-DNA (Fig. 1) (19–21). tc-oligodeoxynucleotides can be
synthesized using standard phosphoramidite chemistry, are
resistant to 3′-exonucleases and show strong binding properties to
complementary RNA. The high thermal stability of tc-DNA–RNA
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duplexes prompted us to further investigate its biological proper-
ties and its potential for antisense applications.
The results from the present study suggest that tc-oligodeoxy-
nucleotides up to 17 nt in length still recognize complementary
RNA with higher affinity compared with 2′-O-Me-PS-RNA.
Furthermore, tc-oligodeoxynucleotides are stable in serum, do
not activate RNase H and show up to 100-fold increase in
antisense activity relative to 2′-O-Me-PS-RNA in a cellular
model measuring the correction of aberrant splicing of human
thalassemic β-globin mRNAs.
MATERIALS AND METHODS
Synthesis of oligonucleotides
tc-oligodeoxynucleotides were prepared on the 1.3 µmol scale
on a Pharmacia Gene Assembler Special™ DNA-synthesizer
using an adapted phosphoramidite chemistry procedure
described in detail previously (20). Briefly, the decamers
tcd(pAACTGTCACG) and tcd(pCGTGACAGTT) were assem-
bled on a universal solid support (CT-Gen, San Jose, CA) and
equipped with a 5′-terminal phosphate group (chemical phos-
phorylation reagent; Glen Research, Sterling, VA) to ensure
chemical stability. The antisense octadecanucleotide (AS)
tcd(pCATTATTGCCCTGAAAGa) and the control oligo-
nucleotide (NS) tcd(pTACCCTTACCTCTCAgTc) were
prepared in analogy, starting from solid supported natural
deoxynucleosides, giving rise to a natural nucleotide residue
(lowercase letters) at their 3′ end. The coupling time was set to
6 min and the usual activator tetrazole was replaced by the
more active 5-(S-benzylthio)-1H-tetrazole (0.25 M in CH3CN)
or 5-(ethylthio)-1H-tetrazole (0.25 M in CH3CN). Coupling
yields were in the range of >95% per step. Post-synthetic
deprotection and cleavage from solid support was performed
in a standard manner (concentration NH3, 16–64 h, 55–65°C).
Crude oligonucleotides were purified by DEAE ion exchange
HPLC and their purity controlled by reversed phase HPLC.
The nucleotide composition of the four tcd-oligonucleotides
was confirmed by ESI-TOF-MS. Oligodeoxyribonucleotides
and oligoribonucleotides were prepared according to standard
methods. The 2′-O-methyl oligoribophosphorothioate, 2′-O-
Me-PS-r(CATTATTGCCCTGAAAGA), was from Eurogentec.
RNase H experiment
Standard manipulations of oligonucleotides and standard
laboratory procedures were performed as described previously
(22). Oligonucleotide tcd(pCGTGACAGTT), or its DNA and
RNA equivalent (0.2 µM, in 60 mM Tris–HCl pH 7.5, 2 mM
DTT, 60 mM KCl and 10 mM MgCl2) were mixed with their
RNA complement r(AACUGUCACG) (0.1 µM, same buffer)
that was radiolabeled at its 5′ end with [γ-32P]ATP and T4
polynucleotide kinase, to a total volume of 30 µl. The mixture
was heated to 80°C, annealed at 37°C and incubated with 0.6 U
Escherichia coli RNase H (Roche Diagnostics). Aliquots of
7 µl were taken at regular time intervals. The reaction was
quenched with gel loading buffer and the mixture loaded on a
20% denaturing polyacrylamide gel. Visualization was
performed on a phosphorimager.
Serum stability tests
Thirty micrograms of the decamer tcd(pCGTGACAGTT) and
its DNA equivalent were dissolved in 400 µl of Dulbecco’s
modified Eagle’s medium (DMEM; Gibco BRL) each, and
incubated at 37°C with 45 µl of 10% heat-deactivated (65°C,
30 min) fetal calf serum (FCS; Gibco BRL). Aliquots of 100 µl
were drawn after regular time intervals and mixed with 100 µl
of 9 M urea in 2x TBE buffer. Of these solutions, 100 µl was
mixed with 50 µl 3 M NaOAc and ethanol precipitated (250 µl
EtOH, –70°C for 4 h then –20°C for 12 h). After centrifugation
for 30 min at 0°C the supernatant was discarded, the pellet
dissolved in 30 µl H2O, lyophilized, and the residue taken up in
TBE buffer (10 µl) and applied on a 20% denaturing polyacryl-
amide gel. The antisense oligonucleotide tcd(pCATTATT-
GCCCTGAAAGa) was treated in the same way. Aliquots were
drawn after 0, 30, 180 and 360 min. Reactions were quenched
with 9 M urea in 2× TBE buffer and phenol extracted. The
aqueous phase was ethanol precipitated and the pellet washed
with 70% EtOH. The pellet was dissolved in 10 ml TBE buffer
and applied on 20% denaturing polyacrylamide gel. Visualiza-
tion of oligonucleotides was performed by staining with ‘stains
all’ (40 mg ‘stains all’ in 400 ml formamide:H2O 1:1).
UV-melting curves
These were recorded on a Varian Cary-100 UV/VIS photo-
spectrometer. A heating–cooling–heating cycle in the temperature
range of 0–90°C with a gradient of 0.5°C/min was applied.
Melting and annealing curves were superimposable in all
cases, indicating equilibrium binding under the conditions
applied. Tm values were defined as the maximum of the first
derivative of the melting curves.
Cell culture, transfections and RNA analysis
HeLa cells stably expressing thalassemic human β-globin
genes carrying the mutations IVS2-654 or IVS2-705 (23,24)
were cultured and transfected with varying amounts of oligo-
nucleotides, complexed with 6 µl (12 µg) lipofectamine
(Invitrogen/Life Technologies), as described previously (25).
For transfection without lipofectamine, 200 µl of DMEM thor-
oughly mixed with varying amounts of oligonucleotides were
incubated with the cells in a 24-well plate for 1 h at 37°C, then
800 µl of DMEM was added for further incubation. Total
cellular RNA was isolated 48 h after the start of transfection
and β-globin mRNA was analyzed by reverse transcription-
polymerase chain reaction (RT–PCR) as described previously (25).
RESULTS
For the following experiments, we synthesized and characterized
the tc-oligonucleotides depicted in Table 1. These oligonucle-
otides, together with that carrying the DNA (d) or the RNA (r)
Figure 1. Representation of the chemical structure of tc-DNA as compared
with DNA.
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backbone as a reference, were used in order to determine the
biological stability and the antisense properties of tc-DNA.
Stability and mismatch discrimination in duplexation of
complementary RNA
First, we investigated the thermal stability of duplexes with
complementary RNA in the given sequence context by means
of UV-melting curve analysis. For the tc-DNA decamer tc2 an
increase in duplex stability by +1.9°C/modification (mod.)
relative to DNA (d2), and by +0.9°C/mod. relative to RNA
(r2), was observed (Table 2). This clearly demonstrates the
enhanced RNA affinity of tc-oligodeoxynucleotides relative to
RNA itself.
An assessment of the impact of base mismatches on duplex
stability was performed in the same sequence context with
complementary RNA decamers displaying mismatched bases
in the center of the sequence (tcT/rX). Relative to the matched
tcT/rA base pair, a typical mismatch leads to an averaged
decrease in Tm of 16°C in the tc-DNA–RNA duplex, as can be
seen from the ∆Tm data compiled in Table 2. As expected, the
T/rG wobble base pairs are nearly isoenergetic to the T/rA base
pairs in both the tc-DNA–RNA and the DNA–RNA hybrids.
Interestingly, the tc-DNA backbone shows the highest discrimi-
nating power, followed by the DNA and the RNA backbone.
Relative to DNA, the gain in selectivity is in the range of 1.1–2.5°C/
mismatch, and relative to RNA in the range of 2.6–4.8°C/
mismatch.
We also measured the duplex stability with complementary
RNA in the context of the AS sequence that was later used for
in vivo experiments. We found a Tm of 77.6°C for the tcAS–RNA
duplex (Fig. 2). This compares with a Tm of 62.3°C for the 2′-
O-Me-phosphorothioate heptadecaribonucleotide (2′-O-Me-PS-
rAS) CAUUAUUGCCCUGAAAG that was used as the reference,
with the same target RNA. Thus, tc-DNA shows an averaged
increase in Tm by about +0.9°C/mod. relative to 2′-O-Me-RNA
also in a longer sequence context. However, we note that, in
this comparison, we have neglected the contribution to binding
of the 3′-terminal deoxyadenosine unit in tcd-AS.
Serum stability
To determine the enzymatic stability of tc-DNA in a biological
environment, we incubated the oligonucleotide decamer tc1 in
heat-deactivated FCS. As can be seen from Figure 3A, there is
no degradation of tc1 over a time span of 5 h. Within the same
time span, most of the DNA control sequence d1 was
degraded. The same experiment with the tcAS oligonucleotide
led to the rapid formation of a new band with a slightly higher
mobility relative to the band of the original oligonucleotide.
This new band was attributed to the oligonucleotide with the
3′-terminal natural deoxyribonucleoside unit lost (Fig. 3B). No
further degradation was observed over the time span of 6 h,
underlining the serum stability of the tc-DNA core sequence.
RNase H activation
RNase H activity leads to the degradation of the RNA strand in
DNA–RNA duplexes and constitutes an important antisense
mechanism. We tested the RNase H susceptibility of tc-DNA–RNA
duplexes in the case of the decamer tc1. As can be seen from
Figure 4, no signs of RNA degradation can be found after
incubation with E.coli RNase H after 5 h in the duplex with
tc1. Under the same conditions, cleavage of the RNA strand in
the duplex with d1 is fast and shows a preference for cleavage
at nucleotides C7 and G5 in the center of the sequence (positive
control). As expected, the pure RNA duplex remains intact
(negative control). Thus, the clear picture emerges that tc-DNA is
unable to elicit RNase H activity.
Correction of aberrant splicing of thalassemic β-globin
mRNA
To test for antisense effects of tc-DNA in vivo, we used a tissue
culture model for alternative splicing established by Kole and
co-workers (23,24). Two β-thalassemic mutations generate new
5′-splice sites (ss) at positions 654 and 705 in the second intron
of the human β-globin gene. Because these mutations activate
a common cryptic 3′-ss at position 579/580 of the same intron,
an aberrant exon containing an in-frame stop codon is included
in the mRNA and β-globin production is abolished. Antisense
2′-O-Me-phosphorothioate oligoribonucleotides targeted to
the aberrant 5′- and cryptic 3′-ss can block the aberrant and
restore the correct splicing pattern by forcing the splicing
machinery to reselect the existing correct ss in cultured HeLa
cells stably expressing the mutant β-globin genes (23,24).
To be able to study antisense effects in both mutant back-
grounds, we used sequences complementary to the cryptic 3′-ss,
Table 1. Sequence information and ESI–-TOF mass spectrometric
characterization of the tc-oligodeoxynucleotides used in the present study
[M-H]– is the molecular anion.
Sequence [M-H]–
(calculated)
[M-H]– (found)
tc1 (pCGTGACAGTT) 3503.2 3503.1
tc2 (pAACTGTCACG) 3472.1 3472.2
tcAS (pCATTATTGCCCTGAAAGa) 6209.2 6208.3
tcNS (pTACCCTTACCTCTCAgTc) 6034.0 6036.0
Table 2. Tm data from UV-melting curves at 260 nm in 10 mM NaH2PO4, 150 mM NaCl at pH 7.0
Duplex concentration = 2 µM.
(pAACTGTCACG) r(pCGUGXCAGUU)
X = A X = U X = G X = C
Tm Tm ∆Tm Tm ∆Tm Tm ∆Tm
r2 52.2°C 39.5°C –12.7°C 50.6°C –1.6°C 39.2°C –13.0°C
d2 42.5°C 27.5°C –15.0°C 40.4°C –2.1°C 28.0°C –14.5°C
tc2 61.6°C 44.1°C –17.5°C 59.0°C –2.6°C 46.0°C –15.6°C
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CUUUCAG’GGCAAUAAUG (ss indicated by apostrophe).
As shown previously (24), the 17mer 2′-O-Me-PS-rAS (identical
to ON-3′CR of that paper) corrected aberrant β-globin mRNA
splicing only very weakly in the IVS2-654 background (Fig. 5A,
lanes 10–15), but more strongly, with an apparent ED50 of
~0.05 µM, in the IVS2-705 background (Fig. 5B, lanes 10–15).
In contrast, the tcAS oligonucleotide (identical in sequence to
2′-O-Me-PS-rAS, except for the additional 3′-terminal dA,
which is partly cleaved off in serum; Fig. 3B) elicited a strong
correction of β-globin mRNA splicing in both mutant back-
grounds (Fig. 5A and B, lanes 4–9). In HeLa-654 cells, up to
~70% of β-globin mRNA could be spliced correctly and the
apparent ED50 was ~0.03 µM. Correct splicing was more or
less complete in HeLa-705 cells and the apparent ED50 was
<0.01 µM.
To test for the specificity of the observed antisense activity,
we synthesized a control tc-DNA oligonucleotide, tcNS. This
oligonucleotide lacks complementarity to the cryptic 3′-ss, but
contains the sequence CCTTACCT whose complement is
similar to the consensus sequence for 5′-ss, AG’GURAGU
(R = A or G). Indeed, oligonucleotide tcNS did not correct the
aberrant β-globin mRNA splicing in HeLa-654 cells (Fig. 5C),
indicating that a six-base complementarity is insufficient to
elicit antisense effects (Table 3). However, a strong correc-
tion of β-globin mRNA splicing was observed in HeLa-705 cells
(Fig. 5D). Inspection of the sequences revealed that, with the
IVS2-705 mutation, oligonucleotide tcNS and the mutant 5′-ss
can form 11 bp separated by a single bulged nucleotide (Table 3).
In view of its less hydrophilic nature, it seemed possible that
tc-DNA could also enter cells and elicit antisense effects
without the help of transfection reagents. When this was tested
in the same concentration ranges as used for the experiments in
Figure 5, no correction of β-globin mRNA splicing could be
observed (data not shown). However, with oligonucleotide
concentrations of 10 or 40 µM, oligonucleotide tcAS, but not
2′-O-Me-PS-rAS, induced correct β-globin mRNA splicing in
both HeLa-654 and HeLa-705 cells (Fig. 6). In HeLa-705 cells,
a weak antisense effect could be observed down to 2 µM of
Figure 2. UV-melting curves (260 nm) of the duplexes of 2′-O-Me-PS-AS
(diamonds) and tcd-AS (triangles) with the corresponding RNA complement
r(pUCUUUCAGGGCAAUAAUG) in 10 mM NaH2PO4, 150 mM NaCl, pH 7.0
(2 µM duplex concentration).
Figure 3. Polyacrylamide gel (20%) showing the time course of the FCS
mediated degradation of oligonucleotides d-1 and tcd-1 (A) and tcd-AS (B) at
the indicated time intervals. Bands were visualized by staining with ‘stains all’.
Figure 4. Autoradiogram of a 20% denaturing polyacrylamide gel showing the
RNase H mediated cleavage of r(AACUGUCACG) by d-1 (lanes 1–4), tcd-1
(lanes 5–8) and r-1 (lanes 9–12) at 1, 30, 120 and 300 min each.
Figure 5. Correction of β-globin mRNA splicing after lipofection of tc-DNA
oligonucleotide. Total RNA from HeLa cells expressing the human β-globin
gene with either the IVS2-654 or IVS2-705 mutation, which result in the inclusion
of an aberrant exon between the normal exons 2 and 3, was subjected to RT–PCR
with primers in exons 2 and 3. Concentrations (µM) of the transfected oligo-
nucleotides are indicated above the lanes. pos, RT–PCR products from cells
expressing both the aberrant IVS2-654 and correct β-globin mRNA; neg (lanes 2
in A, B and D), RT–PCR with RNA from a mouse cell line not expressing
β-globin; mock (lane 2 in C, lane 3 in A and B), RT–PCR with RNA from cells
transfected with empty liposomes; hd, heteroduplexes between aberrant and
correct RT–PCR products. Note that the aberrantly spliced product is longer in
HeLa-705 than in HeLa-654 cells.
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oligonucleotide tcAS (data not shown). Thus, tc-DNA can
penetrate cells even in the absence of liposomal tranfection
reagents, although higher concentrations are required to obtain
antisense effects.
DISCUSSION
High affinity and selectivity in complementary RNA recognition
is a prerequisite for successful antisense applications. tc-DNA
shares both of these features. In the past, we focused on the
synthesis and biophysical characterization of tc-oligonucle-
otides ≤10 nt in length. Such oligonucleotides show increases
in Tm in the range of 1.9–2.4°C compared with RNA. We were
pleased to find that now even longer oligonucleotides
containing uninterrupted stretches of up to 17 tc units can be
synthesized with the same efficiency. Furthermore, such
oligomers show enhanced RNA-binding properties relative to
2′-O-alkyl-RNA or to morpholino antisense oligonucleotides
(26), and comparable RNA binding properties with respect to the
hexitol DNA analog HNA (15), or the N3′→P5′ phosphor-
amidates (27,28). A comparison with the LNA shows that the
average increase in Tm/mod. is higher in the case of LNA
(17,18,29). However, it appears that all-LNA sequences ≥13 nt
in length tend to self-aggregate, thus inactivating themselves for
RNA recognition (30). This seems not to be the case in tc-DNA
and represents a net advantage.
We found earlier that tc-DNA sequences containing the
bases adenine and thymine are stable against the 3′-exonuclease
snake venom phosphodiesterase (20). Thus, it was not
surprising to find that tc-DNA resists the endo- and exonucleases
present in heat deactivated FCS. This test has often been used
in the past for mimicking tissue culture-like nuclease conditions.
The enhanced stability is the direct result of the structural
changes at the centers C(3′) and C(5′). The fact that the last
natural unit in the oligonucleotide tcAS is rapidly cleaved is an
indication that the structural changes in tc-DNA inhibit the
catalytic step in phosphodiester hydrolysis, and not the binding
step by the enzymes. As a consequence of the inherent high
biostability of tc-DNA the use of corresponding phos-
phorothioates is not necessary. This may help in reducing non-
antisense effects and toxicity. Phosphorothioate groups are
absolutely necessary in the case of DNA, and are of advantage
in the case of 2′-O-alkyl-RNA in order to preserve stability in
cellular environments. A more stringent test for the biostability of
tc-DNA in fresh serum or in vivo will, however, be necessary in
the next phase of evaluation.
Most of the sugar-modified antisense oligonucleotides are
not able to induce RNase H activity in complex with RNA.
Especially analogs that emulate RNA structure (RNA analogs)
as, e.g., 2′-O-alkyl-RNA, LNA (30), HNA (31) and the
N3′→P5′ phosphoramidates (28) are virtually unable to activate
RNase H. Notable exceptions are the arabino-NA and the
2′-fluoro-arabino-NA (32), as well as the newly introduced
analog CeNA (33,34). RNase H binds to DNA and RNA
duplexes and, in some cases, to hybrids between oligonucleotide
analogs and RNA, but these complexes are catalytically inactive.
It is known that RNase H activity strongly depends on minor
groove interactions (35). Thus, the size and shape of the minor
groove and with this the conformational preference of the
oligonucleotide analog are the determining factors for catalytic
activity. The structural preference for an A-type double helical
conformation in duplexes with DNA and with itself classifies
tc-DNA as a structural RNA analog and thus explains its
inability to elicit RNase H activity.
This inability to support RNase H-mediated RNA degradation
means that an antisense activity would have to act by other
means, e.g. by repressing cytoplasmic translation or by
affecting nuclear events such as pre-mRNA splicing. Using an
established system for measuring nuclear antisense effects
(23,24), we were able to show a very significant correction of
splicing of aberrantly spliced thalassemic β-globin pre-mRNAs
in HeLa cells (Fig. 5). The correction obtained at the lowest
dose of tcAS tested (0.003 µM) is comparable with that
obtained with 0.2–0.4 µM of 2′-O-Me-PS-rAS containing the
identical antisense sequence. This means that tc-DNA is
approximately 100 times more efficient than 2′-O-Me-PS-RNA.
In this respect, its efficiency seems comparable with
morpholino and PNA oligonucleotides which showed a similar
degree of superiority to both 2′-O-Me-PS and 2′-O-methoxyethyl-
PS oligonucleotides in a similar test system, but using scrape
loading to introduce the oligos into cells, since morpholino
derivatives cannot be transfected with liposome reagents
(36,37).
That tc-DNA may be equivalent to morpholino or PNA
oligonucleotides is also suggested by the fact that antisense
effects were observed even in the absence of transfection
reagents (Fig. 6). With morpholino or PNA oligonucleotides,
such liposome-free transfections could also be obtained, albeit
with low efficiency; for PNA, the efficiency was increased by
attaching one to four lysine residues (36,37). Here, the only
Table 3. Complementarities of oligonucleotide tcNS to IVS2-654 and IVS2-
705 sequences
The upper strand shows the relevant pre-mRNA sequence; apostrophes
indicate the 5′-ss; the nucleotides changed by thalassemic mutations are
shown in bold; and base complementarities are indicated by dots.
Figure 6. Correction of β-globin mRNA splicing after co-incubation (without
liposomes) of tc-DNA oligonucleotide. Total RNA from HeLa-654 and HeLa-705
cells was subjected to RT-PCR with primers in exons 2 and 3. Concentrations
(µM) of the transfected oligonucleotides are indicated above the lanes. pos, neg,
mock and hd, as in Figure 5.
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treatment consisted of a thorough mixing of tc-DNA with the
cell culture medium.
Although the antisense effects of tc-DNA without lipofection
were only seen at considerably higher concentrations, the
direct transfection efficiency can probably still be improved. If
this is the case, tc-DNA antisense oligonucleotides should be
promising reagents for therapeutic in vivo applications. For
this, however, animal toxicity studies would also have to be
carried out.
Considering the strength of the observed nuclear antisense
effects, it will be interesting to see if tc-oligonucleotides also
inhibit mRNA expression either by affecting translation or by
inducing mRNA degradation by means other than RNase H. If
this turns out to be the case, then tc-DNA antisense oligonucle-
otides could be of similar use as morpholino oligonucleotides
or double-stranded RNA interference (reviewed in 38) for
studies of basic biological questions. Moreover, this would
extend the therapeutic potential of tc-DNA beyond applica-
tions where alternative splicing needs to be modulated.
Our observations with the control oligonucleotide tcNS
allow us to draw first conclusions concerning the specificity of
tc-DNA antisense oligonucleotides in cultured cells. The
potential for 6 contiguous bp in the case of the IVS2-654 5′-ss
was insufficient. In contrast, the potential for 8 contiguous bp
separated from 3 further bp by a single bulged nucleotide at the
IVS2-705 5′-ss was sufficient to elicit an antisense effect
similar to that seen with oligonucleotide tcAS (Fig. 5).
However, it must be noted that the 5′-ss created by the IVS2-654
and IVS2-705 mutations are more efficient targets for antisense
oligonucleotides than the cryptic 3′-ss targeted by oligonucleotide
tcAS (24).
tc-oligonucleotides show improved pairing selectivity to
their target, compared with RNA or DNA (Table 2). However,
with longer sequences an overall increased thermal stability of
a matched duplex is typically also associated with an overall
increased stability of a mismatched duplex. This is a severe
handicap in the application of high-affinity antisense probes.
One way out could consist of the design of oligonucleotides
that are as short as possible in order to discriminate
mismatches more efficiently, but that are still long enough to
maintain target specificity.
Our experiments imply that tc-DNA antisense sequences of
11 nt (or shorter) may be sufficient to obtain antisense effects
in vivo. This compares favorably with the longer antisense
sequences commonly used for other types of oligonucleotides.
The finding is also in agreement with the high melting tempera-
tures observed for tc-DNA–RNA hybrids (Table 2). For potential
applications, this shorter length requirement would also translate
into lower costs and higher yields, and potentially even better
cellular transfer properties, of the oligonucleotides.
The question of ss specificity must still be analyzed in more
detail. The control oligonucleotide tcNS was designed to fit an
unrelated 5′-ss. Its efficient antisense effect in HeLa-705 cells
implies a certain risk when targeting sites with long consensus
sequences. Perhaps 5′-ss, with their rather extensive sequence
conservation, will show too much cross-reactivity. In contrast,
3′-ss, with their shorter consensus sequence, may represent
more specific targets. As an alternative in the case of 5′-ss, one
could shift the antisense sequence more into the less conserved
exonic part. Future analyses should show precisely what the
minimum length requirement is and how cross-reactivity,
potentially translating into unwanted side-effects, can be
avoided.
In conclusion, this study establishes that tc-DNA oligo-
nucleotides can very efficiently mediate antisense effects that
are of considerable potential both for medical applications and
studies of basic biology.
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